News AbbVie bags first approval for cancer ADC Emrelis AbbVie has claimed its first global regulatory approval, from the FDA, for its C-met-targeting lung cancer ADC Emrelis.
News Akeso PD-1 inhibitor cleared as Keytruda challenger advances Akeso has bagged an FDA approval for its PD-1 inhibitor penpulimab and reported new data on highly-touted PD-1/VEGF bispecific ivonescimab.
News CRUK scientists find new tool to test lung cancer therapies Researchers in the UK have developed a lung cancer cell line that they believe could be an important new tool for the discovery of new therapies.
News AZ grabs pair of EU approvals for top cancer drugs AstraZeneca is celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to its top-seller Tagrisso.
News BeiGene abandons TIGIT antibody after lung cancer flop BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.
News J&J throws the gauntlet down to AZ with new survival data New survival data from MARIPOSA for Johnson & Johnson's Rybrevant/Lazcluze combination in lung cancer could spell trouble for AstraZeneca.
News UK project addresses capacity issue in CGT manufacturing A UK consortium has been set up to tackle a major issue in the development of cell and gene therapies (CGT) – a lack of manufacturing capacity.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
